Logo

DRTSW

Alpha Tau Medical Ltd.

DRTSW

Alpha Tau Medical Ltd. • NASDAQ
$0.34 ▲ 0.74% (+0.00)
Market Cap $29.20 M
52w High $0.34
52w Low $0.30
Dividend Yield 0%
P/E 0
Volume 10.25K
Outstanding Shares 85.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $-48.642M ▼ $-11.686M ▼ 0% $-0.14 ▼ $-10.454M ▼
Q2-2025 $0 $9.648M ▲ $-10.114M ▼ 0% $-0.13 ▼ $-9.177M ▲
Q1-2025 $0 $9.308M ▼ $-8.691M ▲ 0% $-0.12 ▲ $-9.308M ▼
Q4-2024 $0 $10.274M ▲ $-9.476M ▼ 0% $-0.14 ▼ $-5.397M ▲
Q3-2024 $0 $8.29M $-6.924M 0% $-0.099 $-8.021M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $72.211M ▼ $104.694M ▼ $27.11M ▲ $77.584M ▼
Q2-2025 $79.699M ▲ $110.954M ▲ $24.331M ▼ $86.623M ▲
Q1-2025 $51.636M ▼ $80.928M ▼ $24.603M ▲ $56.325M ▼
Q4-2024 $59.6M ▼ $86.204M ▼ $23.538M ▲ $62.666M ▼
Q3-2024 $65.222M $90.727M $21.329M $69.398M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.686M ▼ $0 $0 $0 $-8.259M ▼ $0
Q2-2025 $-10.114M ▼ $0 $0 $0 $7.026M ▲ $0
Q1-2025 $-8.691M ▲ $0 $0 $0 $-8.748M ▼ $0
Q4-2024 $-9.476M ▼ $0 $0 $0 $8.251M ▲ $0
Q3-2024 $-6.924M $0 $0 $0 $2.85M $0

Five-Year Company Overview

Income Statement

Income Statement Alpha Tau is still a pure R&D, clinical‑stage company with no commercial revenue yet. The income statement is driven almost entirely by research, clinical, and overhead spending, which has led to recurring losses each year. The level of losses appears relatively steady rather than exploding, but they are persistent, reflecting the long development cycle typical in biotech. Profitability will likely depend on successful approvals and commercialization of Alpha DaRT rather than small cost tweaks. Until that inflection, the income statement will likely remain loss‑making and heavily research‑oriented.

Balance Sheet

Balance Sheet The balance sheet shows a small but growing asset base, with equity moving from negative into positive territory over the past few years, which is a constructive sign. Debt levels appear modest, suggesting the company is not heavily leveraged and is not relying primarily on borrowing to fund its trials. Cash balances are present but not large, implying a finite funding runway that will likely require additional capital over time if revenue does not start to flow. Overall, the structure is light and relatively clean, but also clearly in “build” mode rather than in a mature, self‑funding phase.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing spending on research, clinical trials, and company infrastructure without any offsetting product sales. Capital spending is limited, so the cash burn is driven mainly by operating activities rather than large facilities or equipment projects. Free cash flow remains negative, meaning the business depends on external funding sources such as equity raises or partnerships. The burn profile looks controlled rather than explosive, but it still represents a continuous drain until there is a path to commercial receipts.

Competitive Edge

Competitive Edge Alpha Tau’s competitive positioning is unusually strong for a small clinical‑stage company, thanks to its proprietary Alpha DaRT platform and first‑mover status in localized alpha‑particle radiation therapy. The technology is differentiated by its ability to deliver very high, focused radiation doses from within the tumor while trying to spare surrounding tissue, which is a meaningful clinical advantage if consistently validated. Its potential applicability across many different solid tumors and in combination with other therapies broadens the opportunity and strengthens the strategic moat. At the same time, the company operates in a highly competitive oncology market dominated by large pharma and device players, and its current advantage rests on patents, clinical data, and speed to regulatory approval. Any delays, competing technologies, or safety/efficacy concerns could narrow this lead.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of this company: Alpha DaRT is a platform technology with the potential to be used across multiple tumor types, from superficial skin cancers to deep, hard‑to‑treat tumors like pancreatic or brain cancers. The company is running or planning a wide range of trials, including combinations with chemotherapy and explorations in several major organs, which indicates an aggressive and ambitious R&D strategy. Early clinical results, such as strong responses in skin cancer trials with manageable side effects, are encouraging but still need broader and longer‑term validation. Building a dedicated manufacturing facility in the U.S. signals confidence in eventual commercialization but also adds execution and timing risk. Overall, the story is heavily R&D‑driven, with value tied to trial outcomes, regulatory reviews, and the ability to translate scientific promise into scalable medical practice.

Summary

Alpha Tau is a classic early‑stage biotech: scientifically ambitious, commercially pre‑revenue, and financially dependent on external capital while it advances its core technology. The financial statements show a controlled but persistent cash burn, a cleaner and improving balance sheet, and a business model that has not yet turned the corner into sales or profits. Strategically, the company appears to have a meaningful technological edge and a potentially broad cancer treatment platform, which, if successfully validated and approved, could transform its financial profile. However, the path is long and uncertain, with key dependencies on clinical trial success, regulatory approvals in multiple regions, manufacturing scale‑up, and ongoing funding. The overall picture is one of high scientific potential paired with the usual clinical, regulatory, and financing risks that characterize early‑stage oncology innovators.